亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Incidence of Elevated Expression of wt1 in Primary Myelofibrosis (pmf) and Postpv-, Postet Myelofibrosis and Its Dynamics during Ruxolitinib Treatmeny

鲁索利替尼 骨髓纤维化 医学 内科学 入射(几何) 脾脏 胃肠病学 免疫学 肿瘤科 骨髓 光学 物理
作者
Nadiya Siordiya,Ekaterina Lisina,Pavel Butylin,Natalia Matuhina,Константин Богданов,Anna Silutina,Elza Lomaia,Andrey Zaritskiy,Marina Konopleva
出处
期刊:Blood [American Society of Hematology]
卷期号:128 (22): 5498-5498 被引量:1
标识
DOI:10.1182/blood.v128.22.5498.5498
摘要

Abstract Background. Wt1 expression is thoroughly studied in acute myeloblastic leukemia and widely used for disease response monitoring.Its role in MPN is less known. Aim. The aim of the study was to reveal the incidence of elevated Wt1 expression in PMF and secondary MF, as well as to find out clinical significance during ruxolitinib therapy. Patients and methods. 38 pts were included ( Primary Mf-31, post PV- and post ET Mf- 8, males - 12, females- 26). Wt1 expression in peripheral blood was studied by qPCR at diagnosis and during ruxolitinib treatment using Quiagen kit. Dynamics of Wt1 expression was studied in 20 pts treated by ruxolininib. Spleen size was measured in cm below costal margin. Results. Wt1 increased expression was found in 35/38 pts. Correlation of Wt1 expression and DIPSS was not found. The relation between blast cell and Wt1 expression was studied by dividing pts in 3 subgroups according to the number of blast cells in peripheral blood- 0, 1-2, >2. Wt1 expression was lowest in the 1st group, and the highest in the 3rd group((p<.05). Ruxolitinib treatment resulted in the decrease of spleen size and parallel decrease of Wt1 level( p<.05 -Fig1).Pts with transformation to acute leukemia(5) had higher level of Wt1 than before transformation. Conclusion. Wt1 expression is elevated in the majority of pts with PMF as well as in secondary MF. Correlation was found with blast level and spleen size. Wt1 could be used for monitoring efficacy of ruxolitinib therapy Disclosures Konopleva: Reata Pharmaceuticals: Equity Ownership; Abbvie: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Stemline: Consultancy, Research Funding; Eli Lilly: Research Funding; Cellectis: Research Funding; Calithera: Research Funding.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xjcy应助科研通管家采纳,获得10
21秒前
嗯哼应助科研通管家采纳,获得20
21秒前
licaoran完成签到,获得积分20
38秒前
科研通AI2S应助toivy采纳,获得10
1分钟前
xjcy应助科研通管家采纳,获得10
2分钟前
xjcy应助科研通管家采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
FashionBoy应助reborn采纳,获得10
2分钟前
2分钟前
Otter完成签到,获得积分10
2分钟前
2分钟前
叶123完成签到,获得积分10
3分钟前
3分钟前
reborn发布了新的文献求助10
3分钟前
猪仔5号完成签到 ,获得积分10
4分钟前
4分钟前
嗯哼应助科研通管家采纳,获得20
4分钟前
嗯哼应助科研通管家采纳,获得20
4分钟前
xjcy应助科研通管家采纳,获得10
4分钟前
cycycycycyy发布了新的文献求助10
4分钟前
852应助Mannone采纳,获得30
4分钟前
cycycycycyy完成签到,获得积分10
4分钟前
4分钟前
Mannone完成签到,获得积分10
4分钟前
Mannone发布了新的文献求助30
4分钟前
MIO完成签到,获得积分10
5分钟前
5分钟前
5分钟前
科研通AI2S应助reborn采纳,获得10
6分钟前
6分钟前
xjcy应助科研通管家采纳,获得10
6分钟前
xjcy应助科研通管家采纳,获得10
6分钟前
DrWang发布了新的文献求助10
6分钟前
姚老表完成签到,获得积分10
6分钟前
6分钟前
阿柴发布了新的文献求助10
7分钟前
7分钟前
充电宝应助阿柴采纳,获得10
7分钟前
7分钟前
reborn发布了新的文献求助10
7分钟前
高分求助中
Contemporary Issues in Evaluating Treatment Outcomes in Neurodevelopmental Disorders 1000
rhetoric, logic and argumentation: a guide to student writers 1000
QMS18Ed2 | process management. 2nd ed 1000
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
A Chronicle of Small Beer: The Memoirs of Nan Green 1000
From Rural China to the Ivy League: Reminiscences of Transformations in Modern Chinese History 900
Eric Dunning and the Sociology of Sport 850
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 免疫学 细胞生物学 电极
热门帖子
关注 科研通微信公众号,转发送积分 2915857
求助须知:如何正确求助?哪些是违规求助? 2555460
关于积分的说明 6912400
捐赠科研通 2216416
什么是DOI,文献DOI怎么找? 1178047
版权声明 588370
科研通“疑难数据库(出版商)”最低求助积分说明 576593